Építés alatt – nem éles oldal
Belépés
Leállítva2. fázis

This Study Will Evaluate the Safety, Tolerability, and Efficacy of ANB032 in Subjects with Moderate to Severe Atopic Dermatitis (AD).

A legfontosabb adatok

Ki végzi
AnaptysBio, Inc.
Hol
Anaheim, Ann Arbor, Atlanta, Auburn Hills, Baton Rouge, Baytown, Boise, Cerritos, Charlotte, Clarksville, Dallas, Detroit, Doral, Flossmoor, Fountain Valley, Fremont, Frisco, Hazelwood, Katy, Lancaster, Las Vegas, Lomita, Mason, Merrillville, Methuen, Miami, Nashville, New Albany, Oxnard, Pasadena, Philadelphia, Portland, Saint Joseph, San Antonio, Santa Monica, Spokane, Troy és Wilmington (Egyesült Államok)Mind a 41 helyszín megnézéseMég 6 másik országban, 37 helyszínen
Azonosító
Állapot
Leállítva
Fázis
2. fázis
Résztvevők
201 fő vett részt
Kezdés
2023. jún. 13.
Befejezés
2025. jan. 7.
A vizsgálat típusa
Beavatkozással járó, 4 csoportAz egyik csoport placebót (hatóanyag nélküli szert) kap, összehasonlításként.
A vizsgált kezelések
  • ANB032
  • Placebo
A regiszteradat frissítve
2025. február 14.
Miért állt le
ANB032 did not meet the primary endpoint in moderate-to-severe atopic dermatitis

Ki vehet részt

Életkor
18 év – 65 év
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 10 feltétel megnézéseKevesebb

Ki vehet részt

  • Male or female aged 18 to 65 years and in good general health
  • Moderate to severe AD for at least 6 months prior to Randomization
  • History of inadequate response to treatment for AD with topical medications or for whom topical treatments are otherwise medically inadvisable
  • EASI score ≥ 16 at Screening and at Randomization
  • vIGA AD score ≥ 3 at Screening and at Randomization
  • AD involved BSA ≥ 10% at Screening and at Randomization

Ki nem vehet részt

  • Not able to tolerate SC drug administration
  • Tanning booth use or extended sun exposure that could affect disease severity or interfere with disease assessments within 4 weeks before Randomization
  • Any factors that in the Investigator's opinion would predispose the subject to develop an infection
  • Known or suspected congenital or acquired immunodeficiency state, or condition that would compromise the subject's immune status

Helyszínek itt: Egyesült Államok

Még 6 másik országban, 37 helyszínen

  • Anaheim, CaliforniaHospital not named in the registry
  • Ann Arbor, MichiganHospital not named in the registry
  • Atlanta, GeorgiaHospital not named in the registry
  • Auburn Hills, MichiganHospital not named in the registry
  • Baton Rouge, LouisianaHospital not named in the registry
  • Baytown, TexasHospital not named in the registry
  • Boise, IdahoHospital not named in the registry
  • Cerritos, CaliforniaHospital not named in the registry
  • Charlotte, North CarolinaHospital not named in the registry
  • Clarksville, IndianaHospital not named in the registry
  • Dallas, TexasHospital not named in the registry
  • Detroit, MichiganHospital not named in the registry
  • Doral, FloridaHospital not named in the registry
  • Flossmoor, IllinoisHospital not named in the registry
  • Fountain Valley, CaliforniaHospital not named in the registry
  • Fremont, CaliforniaHospital not named in the registry
  • Frisco, TexasHospital not named in the registry
  • Hazelwood, MissouriHospital not named in the registry
  • Katy, TexasHospital not named in the registry
  • Lancaster, CaliforniaHospital not named in the registry
  • Las Vegas, NevadaHospital not named in the registry
  • AnaptysBio Investigative 10-125Lomita, Egyesült Államok
  • Mason, OhioHospital not named in the registry
  • Merrillville, IndianaHospital not named in the registry
  • Methuen, MassachusettsHospital not named in the registry
  • Miami, FloridaHospital not named in the registry
  • Miami, FloridaHospital not named in the registry
  • Miami, FloridaHospital not named in the registry
  • Miami, FloridaHospital not named in the registry
  • Nashville, TennesseeHospital not named in the registry
  • New Albany, IndianaHospital not named in the registry
  • Oxnard, CaliforniaHospital not named in the registry
  • Pasadena, CaliforniaHospital not named in the registry
  • Philadelphia, PennsylvaniaHospital not named in the registry
  • Portland, OregonHospital not named in the registry
  • Saint Joseph, MissouriHospital not named in the registry
  • San Antonio, TexasHospital not named in the registry
  • Santa Monica, CaliforniaHospital not named in the registry
  • Spokane, WashingtonHospital not named in the registry
  • Troy, MichiganHospital not named in the registry
  • Wilmington, North CarolinaHospital not named in the registry

A vizsgálatról

Mit akar kideríteni a vizsgálat

This study will evaluate the safety, tolerability, and efficacy of ANB032 in subjects with moderate to severe atopic dermatitis (AD).

A vizsgálat 4 csoportja

  • ANB032 SC Dose 1A vizsgált kezelés

    This arm will receive treatment SC

    Kezelés: ANB032

  • ANB032 SC Dose 2A vizsgált kezelés

    This arm will receive treatment SC

    Kezelés: ANB032

  • ANB032 SC Dose 3A vizsgált kezelés

    This arm will receive treatment SC

    Kezelés: ANB032

  • PlaceboPlacebo, összehasonlításként

    This arm will receive Placebo SC

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
A Phase 2, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of ANB032 in the Treatment of Subjects with Moderate to Severe Atopic Dermatitis
A regiszteradat frissítve
2025. február 14.